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Abstract
Human parvovirus 4 (‘PARV4’) is a small DNA tetraparvovirus, first reported in
2005. In some populations, PARV4 infection is uncommon, and evidence of
exposure is found only in individuals with risk factors for parenteral infection
who are infected with other blood-borne viruses. In other settings,
seroprevalence studies suggest an endemic, age-associated transmission
pattern, independent of any specific risk factors. The clinical impact of PARV4
infection remains uncertain, but reported disease associations include an
influenza-like syndrome, encephalitis, acceleration of HIV disease, and foetal
hydrops. In this review, we set out to report progress updates from the recent
literature, focusing on the investigation of cohorts in different geographical
settings, now including insights from Asia, the Middle East, and South America,
and discussing whether attributes of viral or host populations underpin the
striking differences in epidemiology. We review progress in understanding viral
phylogeny and biology, approaches to diagnostics, and insights that might be
gained from studies of closely related animal pathogens. Crucial questions
about pathogenicity remain unanswered, but we highlight new evidence
supporting a possible link between PARV4 and an encephalitis syndrome. The
unequivocal evidence that PARV4 is endemic in certain populations should
drive ongoing research efforts to understand risk factors and routes of
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Introduction
Human parvovirus 4 (‘PARV4’) was first described in 20051, 
but many important features of its epidemiology, transmission, 
and clinical significance remain elusive2. PARV4 is a small 
non-enveloped, single-stranded DNA virus with a genome of 
approximately 5 kb, translated as two major and two minor open 
reading frames. Classified as a member of the genus Tetraparvo-
virus, in the family Parvoviridae (sub-family Parvovirinae), it 
sits phylogenetically alongside porcine and bovine hokoviruses3, 
while its closest human-tropic relatives are well-characterised 
B19V (genus Erythroparvovirus) and human bocaviruses (genus 
Bocavirus) (Table 1).
Ongoing investigation of PARV4 is being driven mainly by 
several intriguing features of its distribution: it is endemic in 
certain geographic areas4, but elsewhere is found confined only 
to certain high-risk groups5. The first reported identification of 
PARV4 was from an injecting drug user with hepatitis B virus 
(HBV) infection, who was screened for viral infections following 
presentation with influenza-like symptoms1. Based on this index 
case, subsequent studies in North America and Western Europe 
focused mainly on groups with risk factors for parenteral infec-
tion and those infected with other blood-borne viruses (BBVs). 
In these settings, a clear picture has emerged in which PARV4 
infections are consistently and strongly associated with HIV, 
HBV and HCV, mostly in the setting of persons who inject drugs 
(PWIDs) and those with a history of multiple transfusion5–10. 
Despite attempts to identify it outside this setting, infection has not 
been detected in household contacts of seropositive individuals11 
and is infrequent in the general population6,12.
However, groups working in Africa have reported a completely 
different population epidemiology: in this setting, the detection 
frequency of PARV4 IgG (indicative of current or past exposure) 
ranges from 30% to 50% in the general population, without any 
consistent relationship with BBVs4,13–15. Acute infections associated 
with viraemia were detected at a frequency of 8.5% among young 
children in Ghana16.
The clinical syndromes that have been described in association 
with PARV4 are summarised in Table 1 and Figure 1. However, 
there are too few data to make any of these associations secure, 
and attributing causality in a robust way is inevitably challenging.
This article seeks to summarise recent advances that have been 
made in understanding and characterising the epidemiology, 
immunology, phylogeny, and pathophysiology of PARV4. We have 
maintained a primary focus on updates made since our previous 
review of the topic in 20142, although we have also drawn upon 
some older references where they are fundamental in supporting 
our current understanding. Crucially, there are still many gaps in 
the story; therefore, we have also set out to identify and highlight 
important questions for future study.
New advances in the PARV4 literature
Population prevalence of infection in different geographic 
locations
The most substantial updates to the PARV4 literature are studies 
to determine the prevalence of infection in geographic areas that 
had not previously been represented. This includes new studies in 
Scandinavia17,18, the Middle East19, and South America20,21; we have 
summarised these data in Table 2. Below, we discuss these findings 
with further reference to their applicability to understanding risk 
factors for infection.
Risk factors for PARV4 infection
Based on the strong relationship between PARV4 and HIV, HBV, 
and HCV co-infection in North American and European popula-
tions, several studies have compared PARV4 exposure (screening 
for PARV4 IgG or DNA or both) in HIV-positive and HIV-negative 
groups in different settings. In Iran, HIV infection (with or without 
HCV co-infection) was reported to be associated with a high prev-
alence of PARV4 viraemia (35%)19. However, in this study, the 
background prevalence of viraemia in healthy blood donors was 
also high at 17%19. Higher seroprevalence was also reported in 
Scandinavian subjects in the setting of HIV infection; the PARV4 
IgG detection frequency was 8% among HIV-positive children17, 
Table 1. Potential and confirmed disease associations of parvoviruses in human and animal hosts.
Parvovirus B19 Bocaviruses Bovine and porcine 
hokoviruses
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Figure 1. Cartoon depicting potential clinical associations of human parvovirus 4 (PARV4). The references for each of these are provided 
in Table 1. The question marks highlight that robust and consistent evidence is still lacking for all of these associations. GI, gastrointestinal; 
HIV, human immunodeficiency virus.
while the background population seropositivity rate was less than 
1% in adults and absent in children18,22. Stratification of risk fac-
tors in a French study reported the highest PARV4 prevalence in 
PWIDs, especially among those who were HIV-infected, but also 
among men who have sex with men (MSM), particularly those 
likely to have been exposed in the 1980s12.
Our own study of a cohort of mothers and children in Kimberley, 
South Africa, was comparable to previous reports from sub-Saharan 
Africa in finding an overall PARV4 seroprevalence of 37% with no 
evidence that HIV infection was a risk factor23. Although vertical 
transmission has previously been demonstrated in another setting24, 
there was no concordance between maternal and child serostatus, 
suggesting that maternal transmission is probably not a major con-
tributor to the overall burden of infection in South Africa23. The 
clear trend towards increasing acquisition with age is consistent 
with a broader environmental source of PARV4 infection.
A potential association between PARV4 exposure and infection 
with another BBV, human T-cell lymphotrophic virus (HTLV), was 
described in a Brazilian study21. Among 113 subjects with HTLV-1 
infection, seven (6%) were positive for PARV4 DNA, two of 
whom also had HIV or HCV infection or both. Based on a history 
of blood transfusion in one of these individuals, it was postulated 
that this represents the most likely route of acquisition of all 
three viruses. However, the remaining five cases had no other 
co-infecting BBVs and no history of injecting drug use or blood 
transfusion, leading to the conclusion that other transmission 
routes of PARV4 transmission may also be operating21. Another 
study published by the same group identified PARV4 viraemia 
in 2–5% of individuals either donating blood or receiving trans-
fusions of blood products20. Neither of these Brazilian studies 
screened for PARV4 IgG, so the prevalence of PARV4 exposure 
in this setting remains unknown20,21.
Viral biology/immunology
PARV4 variants characterised to date fall into three distinct 
genetic groups (genotypes 1–3) but show relatively restricted 
sequence variability; in both the non-structural (NS) and capsid- 
encoding genome regions, there is less than 3% amino acid 
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Table 2. Summary of human parvovirus 4 (PARV4) prevalence studies published 2014–2016.
Location of 
cohort
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(8–9% nucleotide) sequence divergence between genotypes 
(representations of diversity can be found in Figure 2 and in 
Supplementary data 1). The even greater restriction of sequence 
diversity within genotypes supports the hypothesis for relatively 
recent transmission to human populations5. Relatively few new 
PARV4 sequences have been reported over the period that we 
have reviewed, and although incremental additions to the sequence 
database have been made over recent years (Figure 3), these have 
not substantially extended the known diversity of this virus.
The distribution of the three genotypes is summarised as follows:
•   Genotype-1 is the genotype currently predominant in Europe 
and North America11,25–27. Sequencing of PARV4-positive 
plasma pools and blood products concentrates from various 
collection years28,29 as well as analysis of the age distributions 
of PARV4-infected study subjects26 suggests that genotype-1 
replaced genotype-2 as the predominantly acquired genotype 
in these regions from the mid-1990s onwards, analogous to 
the genotype replacement that has been described for another 
parvovirus, B19V30. PARV4 sequences derived from a recent 
study in Iran also all grouped as genotype-119.
•   Genotype-2 (formerly known as PARV5) has been identified 
in European and North American cohorts25,27 and appears to 
be the more common genotype in individuals likely infected 
in the 1980s or early 1990s11,26. It was also the predomi-
nant strain reported from Asia31–33. Limited amplification 
of PARV4 genomes from Brazil21 yielded sequences that 
were most similar overall to genotype-2 strains previously 
identified in India32.
•   Genotype-3 has been consistently identified from African 
cohorts13. We have recently derived full-length PARV4 
sequences from an adult and child in South Africa (GenBank 
accession numbers KU871314 and KU871315), which 
cluster together with genotype-3 sequences.
Various reports provide preliminary evidence that PARV4 may 
not be completely cleared after acute infection, suggesting that 
it has the potential for latency and reactivation. Two studies in 
Taiwan have sought to describe serological responses to PARV4 
infection by undertaking longitudinal follow-up of their 
cohorts31,33. Among a small cohort of health-care workers, IgG 
seropositivity was strikingly high at 60%; half of these had a 
Figure 2. Variability scan of human parvovirus 4 (PARV4) genomes, showing mean pairwise nucleotide distances of sequential 250 
base fragments, incrementing by 25 bases between data points. Sequence  comparisons  were  between  10  genotype-1  (DQ873386, 
DQ873387, DQ873388, DQ873389, EU175856, EU200667, EU546204, EU546210, EU546211, and NC007018), 13 genotype-2 (DQ873390, 
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Figure 3. Phylogeny of published complete or near complete human parvovirus 4 (PARV4) genome sequences as inferred from 
complete NS (ORF1) nucleotide sequences (equivalent to nucleotides 283–2271 of the reference sequence NC007018). Sequences 
published since 2014 are highlighted with filled circles. The evolutionary history was inferred by using the maximum likelihood model. The 
optimum maximum  likelihood model  (lowest Bayesian  information criterion score and  typically greatest maximum  likelihood value  for  the 
nucleotide sequence alignment) was first determined and used for phylogenetic reconstruction. This was the Tamura 3-parameter model with 
a gamma distribution. Bootstrap support of branches (500 replications) is indicated.
positive IgM that was sustained over the study period, and virae-
mia was detected at one of several sampling time-points33. In the 
second study, this time focusing on a high-risk PWID cohort, IgM 
was reported as remaining positive for up to 21 months31. 
Meanwhile, in vitro experiments have demonstrated a sustained 
high-magnitude ex vivo CD8+ T-cell response to PARV4 NS 
peptide34. Prolonged IgM-positivity and sustained high-magnitude 
T-cell responses together suggest a sustained or relapsing/remitting 
exposure to viral antigen. Tissue homing and sites of latency are 
unknown, but existing data suggest that bone marrow, the res-
piratory tract, liver and gut might represent potential sites of 
viral replication5,15,26,27,35,36. Skin has also been highlighted as a 
potential reservoir site for B19V37, although—to the best of our 
knowledge—no study has investigated this as a site of PARV4 
replication. The role of capsid proteins in parvovirus infections 
has been recently reviewed38, although there are no specific 
functional or structural data for PARV4.
Clinical associations of PARV4
To date, determining the clinical impact (if any) of PARV4 
infection remains perhaps the most uncertain area of research into 
this virus, despite the medical importance of establishing such 
disease associations. A wide range of potential infection outcomes 
has been proposed (summarised in Table 1), but the evidence for a 
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pathogenic role of PARV4 in any of these has not been significantly 
expanded in recent years.
The most significant addition to the literature builds on an earlier 
report linking PARV4 with an encephalitis syndrome in Bellary, 
South India32. Further efforts have been made to substantiate this 
important potential disease association by screening ten patients in 
Northern India with an acute encephalitis syndrome in whom other 
viral causes had been ruled out. The investigators identified PARV4 
DNA in the cerebrospinal fluid (CSF) and blood of two39. However, 
it remains uncertain whether PARV was actually the agent of the 
observed disease, or a bystander that was coincidentally detected in 
a highly exposed population. Neither this nor the previous study32 
included a control group in which the background incidence of 
PARV4 infections could have been evaluated. It is additionally pos-
sible that detection of PARV4 DNA in CSF in these two studies 
simply represents reactivation of the virus in the central nervous 
system in the context of other pathology.
Developing and refining methods for the study of PARV4
One approach to the determination of PARV4 serostatus is to use 
an enzyme-linked immunosorbent assay (ELISA)-based approach 
with an optical density read-out that is calibrated as positive 
or negative. However, the choice of a fixed cut-off above which 
threshold samples are termed ‘positive’ can be problematic and 
evidently has bearing on the final estimation of prevalence; the 
choice of this threshold evidently affects sensitivity and spe-
cificity of the test, and may need to be altered in light of the 
consideration of the primary reason for screening (diagnosis 
versus seroepidemiology). This effect is exemplified by recently 
published simulations, alongside discussion of alternative 
approaches that set out to quantify population prevalence40. One 
of these is to use ‘mixture models’, which estimate population 
seroprevalence from the complete screened dataset rather than 
classifying each individual sample as positive or negative40. 
Application of these new analytical methods to existing PARV4 
serosurvey datasets has yet to be performed but may refine preva-
lence estimates and allow for better comparison between studies.
A novel polymerase chain reaction (PCR) assay for genotyping 
and quantifying PARV4 was published in 201441. The authors 
report that their method reliably discriminates between PARV4 
genotypes, and use quantitative PCR to measure viraemia41.
Practical implications: human tissue for transfusion and 
transplantation
Consistently high detection frequencies of anti-PARV4 antibod-
ies in sera of haemophiliac individuals provide strong evidence for 
some transmission via the use of clotting factor concentrates11,42. 
Although modern procedures for viral inactivation may effectively 
remove parvovirus infectivity, PARV4 is more robust than B19V 
to heat and other virus inactivation methods used in blood prod-
uct manufacture, and there is ongoing discussion about the need to 
implement donation screening for PARV4 DNA and/or to enhance 
measures to ensure that the virus is eradicated from blood products 
for transfusion10,43–45.
Blood donors have been screened as a component of several studies 
(see representative data in Table 1 for recent examples). PARV4 
IgG screening of UK blood donors identified a seropositivity rate of 
4.8%, but no donations were PCR-positive10. However, the results 
of such studies are disparate, as a previous study from the same 
group did find PARV4-positive pools46. Studies outside the UK that 
have screened blood donors by PCR have found frequencies of 0% 
in Italy35; 3–4% in Brazil20, Thailand9, and North America25; and as 
high as 17% in Iran19.
Solid organ transplant recipients are a more difficult population to 
assess and are unsurprisingly less well represented in the literature; 
no new articles on this topic have been published in the past two 
years. However, since 2008, an Italian study has reported finding 
PARV4 in a small number of renal transplant recipients35, and a 
French cohort of lung transplant patients reports that 14% were 
viraemic47. The clinical significance of these findings and whether 
these cases represent reactivation of autologous virus in the context 
of immunosuppression or transmission of donor virus at the time of 
organ transplantation have yet to be explored.
Insights from new animal data
There is increasing evidence that infections with porcine and 
bovine hokoviruses are endemic in both wild and domestic 
animals; most of these recent animal data are simply detection 
studies and do not provide any new data about pathogenicity. These 
include the frequent detection of porcine hokovirus in hunted wild 
boar in Portugal48 and a bovine hokovirus in domestic yaks49. In 
South America, another hokovirus was found to be endemic in 
a survey of Brazilian pig herds, in which post-weaning multi- 
systemic wasting syndrome was common50, and a novel porcine 
hokovirus (referred to as porcine parvovirus 6, or PPV6) has been 
associated with foetal loss in pigs in China51,52.
As livestock pathogens, these organisms are potentially implicated 
as a cause of significant economic losses in agriculture52,53. How-
ever, since most of the suggested pathogenicity has been attributed 
to protoparvoviruses or copiparvoviruses, we cannot necessarily 
infer any significance to tetraparvoviruses. Nevertheless, the wide-
spread isolation of parvoviruses, particularly from domestic ani-
mals, should raise concerns about the potential risk of inter-species 
transmission events leading to the possibility of more pathogenic 
viruses crossing into human populations.
A recent study of microRNA expression in porcine parvovirus 
infection describes upregulation of microRNAs that are known 
to be immune system regulators52. In the longer term, this kind of 
study may provide further insights into the nature and mechanism 
of host-virus interactions.
Discussion and conclusions
As this review illustrates, our understanding of PARV4 continues 
to advance gradually, but there are still many important unresolved 
questions, and the significance of this infection to human health 
remains uncertain. The striking difference in population epidemi-
ology in developed and developing countries currently remains 
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unexplained, and it is uncertain to what extent differences in virus 
properties or host characteristics account for the marked differences 
in population seroprevalence. For the former, it is plausible that 
genotype-specific amino acid substitutions underpin differences 
in the route, mechanism, or efficiency of transmission. From the 
host side, it is possible that differences in human genetics, preva-
lent co-infections, or environmental, behavioural, or iatrogenic 
exposure account for differences in seroprevalence and risk factors 
between continents.
Ongoing diligent scrutiny of carefully characterised clinical cohorts 
will be required to cement any associations with human disease; this 
may require larger collaborative efforts than have been undertaken 
to date. An in vitro system is still needed to help us understand 
the biology of PARV4 in more detail, including characterisation 
of tissue tropism, productivity of cellular infection, the influence 
of co-infecting viruses, and the mechanisms underlying viral 
suppression by the immune system.
This review highlights a number of compelling arguments in favour 
of advancing our understanding of PARV4. Firstly, this agent is 
endemic in some human populations; even if pathology emerges in 
only a small subset of infected individuals, this may still be impor-
tant in terms of overall case numbers. Putative associations with 
significant pathology may be particularly relevant for certain vul-
nerable groups, including those with other chronic viral infection 
(HIV, HBV, or HCV), those with solid organ or bone marrow trans-
plantation, and recipients of human blood or tissue transplant11,35. 
Secondly, we know that viral infections are relevant to the host in 
more diverse ways than just the effects of primary infection; they 
may shape immune ontogeny, influence the outcomes of infection 
with other pathogens54, and drive or control oncogenesis. Under-
standing viral biology also allows us to draw on these agents as a 
resource for vaccine design, as exemplified by the adenovirus con-
structs used in vaccine trials for HIV55,56 and HCV57.
Therefore, whether PARV4 turns out to be an innocent bystander or 
an elusive human pathogen, there are robust reasons for advocating 
ongoing clinical and research efforts to further our understanding 
of epidemiology and the current and future potential significance 
to human health.
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